Hyperfine, Inc. Stock Research

Market Summary

USD1.27-0.13

Market Closed

-9.29%

HYPR Stock Price

HYPR RSI Chart

HYPR Valuation

Market Cap

89.5M

Price/Earnings (Trailing)

-1.04

Price/Sales (Trailing)

15.37

EV/EBITDA

0.5

Price/Free Cashflow

-1.17

HYPR Price/Sales (Trailing)

HYPR Profitability

EBT Margin

-1479.40%

Return on Equity

-63.85%

Return on Assets

-58.11%

Free Cashflow Yield

-85.46%

HYPR Fundamentals

HYPR Revenue

Revenue (TTM)

5.8M

Revenue Y/Y

532.88%

Revenue Q/Q

53.16%

HYPR Earnings

Earnings (TTM)

-86.2M

Earnings Y/Y

19.65%

Earnings Q/Q

43.13%

Price Action

52 Week Range

0.684.10

(Low)(High)

Last 7 days

-10.6%

Last 30 days

-8.0%

Last 90 days

42.7%

Trailing 12 Months

-64.0%

HYPR Financial Health

Current Ratio

11.54

HYPR Investor Care

Shares Dilution (1Y)

3626.32%

Diluted EPS (TTM)

4.13

Financials for Hyperfine

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	51.4%	5,826,000	3,849,000	2,674,000	1,496,000	1,413,333
Gross Profit	117.7%	154,000	-872,000	-806,000	-1,167,000	-910,000
Operating Expenses	-2.4%	86,486,000	88,568,000	80,028,000	63,701,000	50,756,000
S&GA Expenses	4.2%	15,937,000	15,290,000	13,327,000	10,362,000	6,743,000
R&D Expenses	2.9%	31,830,000	30,930,000	29,702,000	25,842,000	20,500,000
EBITDA	3.7%	-85,099,000	-88,386,000	-87,594,234	-64,125,000	-45,154,000
EBITDA Margin	36.4%	-14.61	-22.96	-23.46	-42.86	-32.77
Earnings Before Taxes	3.6%	-86,190,000	-89,411,000	-80,832,000	-64,851,000	-45,628,000
EBT Margin	36.3%	-14.79	-23.23	-23.70	-43.35	-33.11
Net Income	3.6%	-86,190,000	-89,411,000	-80,832,000	-64,851,000	-51,688,000
Net Income Margin	48.3%	-14.79	-28.63	-13.98	-43.35	-2.40
Free Cahsflow	17.7%	-76,531,000	-92,936,305	-76,674,396	-49,893,000	-41,238,333

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-8.3%	148	162	179	202	81.00
Current Assets	-8.5%	144	157	174	197	76.00
Cash Equivalents	-8.7%	132	145	162	188	65.00
Inventory	-13.9%	4.00	5.00	5.00	4.00	3.00
Net PPE	-1.4%	3.00	3.00	4.00	4.00	3.00
Liabilities	19.2%	13.00	11.00	12.00	16.00	14.00
Current Liabilities	19.2%	12.00	10.00	11.00	16.00	14.00
Shareholder's Equity	-10.3%	135	151	167	186	-101
Retained Earnings	-7.2%	-196	-183	-160	-136	-110
Additional Paid-In Capital	-0.7%	331	334	327	323	9.00
Accumulated Depreciation	13.0%	2.00	2.00	2.00	1.00	-
Shares Outstanding	0.2%	71.00	70.00	70.00	4.00	2.00

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-3.9%	-75,129	-72,278	-66,985	-47,182	-38,729
Share Based Compensation	-31.4%	7,369	10,745	6,901	3,391	-
Cashflow From Investing	38.8%	-1,402	-2,290	-2,849	-2,711	-2,509
Cashflow From Financing	-0.9%	282,656	285,184	176,767	47,252	-

Risks for HYPR

What is the probability of a big loss on HYPR?

57.5%

Probability that Hyperfine stock will be more than 20% underwater in next one year

57.5%

Probability that Hyperfine stock will be more than 30% underwater in next one year.

55.8%

Probability that Hyperfine stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HYPR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Hyperfine was unfortunately bought at previous high price.

Drawdowns

Returns for HYPR

Cumulative Returns on HYPR

Which funds bought or sold HYPR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-06	Rockefeller Capital Management L.P.	unchanged	-	-	2,000	-%
2023-02-15	JANE STREET GROUP, LLC	new	-	9,096	9,096	-%
2023-02-15	HealthCor Management, L.P.	added	41.15	1,032,960	3,259,960	2.99%
2023-02-14	Alyeska Investment Group, L.P.	unchanged	-	22,000	630,000	0.01%
2023-02-14	ROYAL BANK OF CANADA	sold off	-100	-	-	-%
2023-02-14	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-28.57	-37,000	105,000	-%
2023-02-14	GLENVIEW CAPITAL MANAGEMENT, LLC	sold off	-100	-490,000	-	-%
2023-02-14	CAZ INVESTMENTS LP	new	-	40,000	40,000	0.07%
2023-02-14	PERCEPTIVE ADVISORS LLC	sold off	-100	-751,000	-	-%
2023-02-14	Bank of New York Mellon Corp	unchanged	-	396	13,396	-%

Latest Funds Activity

Are funds buying HYPR calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own HYPR

No. of Funds

Hyperfine News

Schedule 13G FIlings of Hyperfine

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	hc sponsor llc	0.0%	0	SC 13G/A
Dec 20, 2022	hc sponsor llc	12.0%	6,634,000	SC 13G/A

HYPR Fair Value

Recent SEC filings of Hyperfine

View All Filings

Date Filed	Form Type	Document
Mar 22, 2023	10-K	Annual Report
Mar 22, 2023	8-K/A	Current Report
Mar 22, 2023	S-8	Employee Benefits Plan
Mar 21, 2023	8-K	Current Report
Mar 10, 2023	8-K	Current Report
Feb 21, 2023	8-K	Current Report
Feb 17, 2023	4	Insider Trading
Feb 17, 2023	4	Insider Trading
Feb 15, 2023	4	Insider Trading
Feb 15, 2023	3	Insider Trading

Latest Insider Trading transactions for HYPR

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-02-16	Gupta Alok	sold	-7,802	1.39	-5,613	chief financial officer
2023-02-16	Siddiqui Khan	sold	-6,442	1.39	-4,635	cmo and chief strategy officer
2022-12-16	HC Sponsor LLC	sold	-	-	-5,534,000	-
2022-12-14	Sainz Maria	bought	4,750	0.95	5,000	president and ceo
2022-12-09	Sainz Maria	acquired	10,561	0.85	12,425	president and ceo
2022-12-09	Sainz Maria	bought	10,561	0.85	12,425	president and ceo
2022-12-08	Sainz Maria	acquired	2,137	0.83	2,575	president and ceo
2022-12-08	Sainz Maria	bought	2,137	0.83	2,575	president and ceo
2022-11-30	ROTHBERG JONATHAN M	bought	187,956	0.82	229,215	-
2022-11-29	ROTHBERG JONATHAN M	bought	33,845	0.72	47,007	-

About Hyperfine

David D. Scott

hyperfine.io

190

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

HYPR Income Statement

2022-12-31

COMBINED AND CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Sales
Total sales	$ 6,814	$ 1,496
Cost of sales
Total cost of sales	5,907	2,663
Gross margin	907	(1,167)
Operating Expenses:
Research and development	28,156	25,842
General and administrative	32,406	27,497
Sales and marketing	14,219	10,362
Total operating expenses	74,781	63,701
Loss from operations	(73,874)	(64,868)
Interest income	761	18
Other expense, net	(51)	(1)
Loss before provision for income taxes	(73,164)	(64,851)
Provision for income taxes	0	0
Net loss and comprehensive loss	$ (73,164)	$ (64,851)
Earnings Per Share, Basic	$ (1.04)	$ (17.57)
Earnings Per Share, Diluted	$ (1.04)	$ (17.57)
Denominator for Basic EPS - Weighted-average common stock	70,449,191	3,690,523
Denominator for Dilutive EPS - Weighted-average common stock	70,449,191	3,690,523
Device
Sales
Total sales	$ 5,246	$ 715
Cost of sales
Total cost of sales	4,231	2,058
Service
Sales
Total sales	1,568	781
Cost of sales
Total cost of sales	$ 1,676	$ 605

HYPR Balance Sheet

2022-12-31

COMBINED AND CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 117,472	$ 188,498
Restricted cash	771	2,662
Accounts receivable, less allowance of $180 and $32 in 2022 and 2021, respectively	2,103	553
Unbilled receivables	454	91
Inventory	4,622	4,310
Prepaid expenses and other current assets	3,194	1,357
Due from related parties	48	14
Total current assets	128,664	197,485
Property and equipment, net	3,248	3,753
Other long term assets	2,139	1,235
Total assets	134,051	202,473
CURRENT LIABILITIES:
Accounts payable	678	2,248
Deferred grant funding	771	2,662
Deferred revenue	1,378	730
Due to related parties		1,981
Accrued expenses and other current liabilities	5,976	8,115
Total current liabilities	8,803	15,736
Long term deferred revenue	1,526	510
Total liabilities	10,329	16,246
COMMITMENTS AND CONTINGENCIES (NOTE 14)
STOCKHOLDERS' EQUITY:
Additional paid-in capital	333,199	322,540
Accumulated deficit	(209,484)	(136,320)
Total stockholders' equity	123,722	186,227
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	134,051	202,473
Class A Common Stock
STOCKHOLDERS' EQUITY:
Common stock	5	5
Class B Common Stock
STOCKHOLDERS' EQUITY:
Common stock	$ 2	$ 2